SVF-004

SVF-004 is a preclinical vaccine candidate being developed by SVF Vaccines for the prevention of Cytomegalovirus (CMV) infection. The vaccine is built upon a platform that utilizes both DNA and mRNA technologies to deliver genetic sequences encoding CMV antigens to the host's cells. This approach is intended to stimulate a comprehensive immune response, including both neutralizing antibodies and T-cell activity, to protect against CMV. CMV is a widespread herpesvirus that can cause severe disease in newborns and immunocompromised individuals, such as organ transplant recipients. SVF-004 represents a modern genetic vaccination strategy aimed at addressing the significant clinical burden of CMV.